SCHEMBL4356830

SCHEMBL4356830

FC(F)(F)Oc1ccc(Nc2cc(N3CCCCC3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 7/20 0.57
GALR1 P47211 4/20 0.57
ABL1 P00519 5/20 0.48
MAPK1 P28482 3/20 0.48
YES1 P07947 2/20 0.48
NTRK1 P04629 1/20 0.48
PIM1 P11309 1/20 0.48
KDR P35968 1/20 0.48
HIPK1 Q86Z02 1/20 0.48
ACP1 P24666 1/20 0.45
BRAF P15056 1/20 0.45
TP53 P04637 2/20 0.45
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
HSD17B10 Q99714 1/20 0.44
BCR P11274 3/20 0.43
BACE1 P56817 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3996030 0.99 GALR2 (0.55) GALR2GALR1ABL1MAPK1YES1
SCHEMBL3998850 0.95 GALR2 (0.57) GALR2GALR1ABL1ACP1BRAF
SCHEMBL4130166 0.91 GALR2 (0.53) GALR2GALR1ABL1MAPK1ACP1
SCHEMBL4001751 0.89 GALR2 (0.52) GALR2GALR1ABL1MAPK1BRAF
SCHEMBL4119573 0.85 ABL1 (0.61) GALR2GALR1ABL1MAPK1BRAF
SCHEMBL3997013 0.83 TP53 (0.52) GALR2GALR1ABL1BRAFTP53
SCHEMBL4127373 0.82 GALR2 (0.61) GALR2GALR1ABL1TP53LMNA
SCHEMBL4358367 0.81 KDM4E (0.50) GALR2GALR1MAPK1ACP1TP53
SCHEMBL10143797 0.81 GALR2 (0.83) GALR2GALR1ABL1TP53LMNA
SCHEMBL3993571 0.81 GALR2 (0.59) GALR2GALR1ABL1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US claimed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP disclosed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP GALR2 1333/4885GALR1 1193/4885ABL1 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.